Diallyl trisulfides, a natural histone deacetylase inhibitor, attenuate HIF-1α synthesis, and decreases breast cancer metastasis

Molecular Carcinogenesis

Volumn 56, Issue 10, 2017, Pages 2317-2331

  Wei, Zhonghong ^a,b   Shan, Yunlong ^a,b   Tao, Li ^c   Liu, Yuping ^a,b   Zhu, Zhijie ^a,b   Liu, Zhaoguo ^a,b   Wu, Yuanyuan ^a,b   Chen, Wenxing ^a,b   Wang, Aiyun ^a,b   Lu, Yin ^a,b  

^a NANJING UNIVERSITY OF CHINESE MEDICINE   (China)

^b Jiangsu Key Laboratory for Pharmacolgy and Safety Evaluation of Chinese Materia Medica   (China)

^c YANGZHOU UNIVERSITY   (China)

Author keywords

breast cancer metastasis; DATS; HDAC inhibitor; HIF 1 ; Trx 1

Indexed keywords

ALLYL SULFIDE; ANGPTL4 PROTEIN; ANTINEOPLASTIC AGENT; CELL PROTEIN; DIALLYL DISULFIDE; DIALLYL TRISULFIDE; FIREFLY LUCIFERASE; GELATINASE A; HISTONE DEACETYLASE INHIBITOR; HYPOXIA INDUCIBLE FACTOR 1ALPHA; L1CAM PROTEIN; LOX PROTEIN; LOXL4 PROTEIN; MESSENGER RNA; RENILLA LUCIFERIN 2 MONOOXYGENASE; TRANSCRIPTION FACTOR SLUG; TRANSCRIPTION FACTOR SNAIL; TUMOR PROTEIN; UNCLASSIFIED DRUG; VASCULOTROPIN A; VON HIPPEL LINDAU PROTEIN; ALLYL COMPOUND; DISULFIDE; HIF1A PROTEIN, HUMAN; SULFIDE;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST CANCER; CANCER PROGNOSIS; CARCINOGENESIS; CELL ADHESION; CELL MIGRATION; CELL MOTILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOWN REGULATION; DRUG SYNTHESIS; EMBRYO; ENZYME ACTIVITY; FEMALE; GARLIC; HUMAN; HUMAN CELL; IN VITRO STUDY; LUCIFERASE ASSAY; LUNG METASTASIS; MDA-MB-231 CELL LINE; METASTASIS INHIBITION; METASTASIS POTENTIAL; MOUSE; MTT ASSAY; NONHUMAN; PRIMARY TUMOR; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN TARGETING; TRANSCRIPTION REGULATION; TRANSLATION REGULATION; TUMOR CELL INOCULATION; TUMOR HYPOXIA; TUMOR MODEL; TUMOR XENOGRAFT; WOUND HEALING ASSAY; ZEBRA FISH; ANIMAL; BREAST NEOPLASMS; DRUG EFFECTS; DRUG SCREENING; GENE EXPRESSION REGULATION; GENE REGULATORY NETWORK; GENETICS; METABOLISM; METASTASIS; TUMOR CELL LINE;

ALLYL COMPOUNDS; ANIMALS; BREAST NEOPLASMS; CELL ADHESION; CELL LINE, TUMOR; DISULFIDES; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE REGULATORY NETWORKS; HISTONE DEACETYLASE INHIBITORS; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; MICE; NEOPLASM METASTASIS; SULFIDES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 85021793746     PISSN: 08991987     EISSN: 10982744     Source Type: Journal    
DOI: 10.1002/mc.22686     Document Type: Article

References (48)

1. Wilson WR, Hay MP. Targeting hypoxia in cancer therapy. Nat Rev Cancer. 2011; 11:393–410.
2. Rankin EB, Giaccia AJ. Hypoxic control of metastasis. Science. 2016; 352:175–180.
3. Vaupel P. Prognostic potential of the pre-therapeutic tumor oxygenation status. Adv Exp Med Biol. 2009; 645:241–246.
4. Knaup KX, Monti J, Hackenbeck T, et al. Hypoxia regulates the sperm associated antigen 4 (SPAG4) via HIF, which is expressed in renal clear cell carcinoma and promotes migration and invasion in vitro. Mol Carcinog. 2014; 53:970–978.
5. Gilkes DM, Semenza GL. Role of hypoxia-inducible factors in breast cancer metastasis. Future Oncol. 2013; 9:1623–1636.
6. Kaelin WG, Ratcliffe PJ, Semenza GL. Pathways for oxygen regulation and homeostasis: the 2016 albert lasker basic medical research award. JAMA. 2016; 316:1252–1253.
7. Erler JT, Bennewith KL, Cox TR, et al. Hypoxia-induced lysyl oxidase is a critical mediator of bone marrow cell recruitment to form the premetastatic niche. Cancer Cell. 2009; 15:35–44.
8. Semenza GL. Hypoxia-inducible factors in physiology and medicine. Cell. 2012; 148:399–408.
9. Luo D, Wang J, Li J, Post M. Mouse snail is a target gene for HIF. Mol Cancer Res. 2011; 9:234–245.
10. Zhang H, Wong CC, Wei H, et al. HIF-1-dependent expression of angiopoietin-like 4 and L1CAM mediates vascular metastasis of hypoxic breast cancer cells to the lungs. Oncogene. 2012; 31:1757–1770.
11. Semenza GL. Defining the role of hypoxia-inducible factor 1 in cancer biology and therapeutics. Oncogene. 2010; 29:625–634.
12. Kaelin WG, Ratcliffe PJ. Oxygen sensing by metazoans: the central role of the HIF hydroxylase pathway. Mol Cell. 2008; 30:393–402.
13. Thomas GV, Tran C, Mellinghoff IK, et al. Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer. Nat Med. 2006; 12:122–127.
14. Arsham AM, Howell JJ, Simon MC. A novel hypoxia-inducible factor-independent hypoxic response regulating mammalian target of rapamycin and its targets. J Biol Chem. 2003; 278:29655–29660.
15. Ellis L, Bots M, Lindemann RK, et al. The histone deacetylase inhibitors LAQ824 and LBH589 do not require death receptor signaling or a functional apoptosome to mediate tumor cell death or therapeutic efficacy. Blood. 2009; 114:380–393.
16. Bai G, Wei D, Zou S, Ren K, Dubner R. Inhibition of class II histone deacetylases in the spinal cord attenuates inflammatory hyperalgesia. Mol Pain. 2010; 6:51.
17. Qian DZ, Kachhap SK, Collis SJ, et al. Class II histone deacetylases are associated with VHL-independent regulation of hypoxia-inducible factor 1 alpha. Cancer Res. 2006; 66:8814–8821.
18. Nian H, Delage B, Ho E, Dashwood RH. Modulation of histone deacetylase activity by dietary isothiocyanates and allyl sulfides: studies with sulforaphane and garlic organosulfur compounds. Environ Mol Mutagen. 2009; 50:213–221.
19. Iciek M, Kwiecień I, Włodek L. Biological properties of garlic and garlic-derived organosulfur compounds. Environ Mol Mutagen. 2009; 50:247–265.
20. Druesne-Pecollo N, Latino-Martel P. Modulation of histone acetylation by garlic sulfur compounds. Anticancer Agents Med Chem. 2011; 11:254–259.
21. Nian H, Delage B, Pinto JT, Dashwood RH. Allyl mercaptan, a garlic-derived organosulfur compound, inhibits histone deacetylase and enhances Sp3 binding on the P21WAF1 promoter. Carcinogenesis. 2008; 29:1816–1824.
22. Kaschula CH, Hunter R, Cotton J, et al. The garlic compound ajoene targets protein folding in the endoplasmic reticulum of cancer cells. Mol Carcinog. 2016; 55:1213–1228.
23. Druesne-Pecollo N, Chaumontet C, Pagniez A, et al. In vivo treatment by diallyl disulfide increases histone acetylation in rat colonocytes. Biochem Biophys Res Commun. 2007; 354:140–147.
24. Druesne N, Pagniez A, Mayeur C, et al. Repetitive treatments of colon HT-29 cells with diallyl disulfide induce a prolonged hyperacetylation of histone H3 K14. Ann N Y Acad Sci. 2004; 1030:612–621.
25. Wallace GC, Haar CP, Vandergrift WA, et al. Multi-targeted DATS prevents tumor progression and promotes apoptosis in ectopic glioblastoma xenografts in SCID mice via HDAC inhibition. J Neurooncol. 2013; 114:43–50.
26. Shan Y, Wei Z, Tao L, et al. Prophylaxis of diallyl disulfide on skin carcinogenic model via p21-dependent nrf2 stabilization. Sci Rep. 2016; 6:35676.
27. Liu Y, Zhu P, Wang Y, et al. Antimetastatic therapies of the polysulfide diallyl trisulfide against Triple-Negative Breast cancer (TNBC) via suppressing MMP2/9 by blocking NF-κB and ERK/MAPK signaling pathways. PLoS ONE. 2015; 10:e0123781.
28. Rouhi P, Jensen LD, Cao Z, et al. Hypoxia-induced metastasis model in embryonic zebrafish. Nat Protoc. 2010; 5:1911–1918.
29. Lee SL, Rouhi P, Dahl JL, et al. Hypoxia-induced pathological angiogenesis mediates tumor cell dissemination, invasion, and metastasis in a zebrafish tumor model. Proc Natl Acad Sci USA. 2009; 106:19485–19490.
30. Zhu Z, Zhao Y, Li J, et al. Cryptotanshinone, a novel tumor angiogenesis inhibitor, destabilizes tumor necrosis factor-α mRNA via decreasing nuclear-cytoplasmic translocation of RNA-binding protein HuR. Mol Carcinog. 2016; 55:1399–1410.
31. Yeo EJ, Chun YS, Cho YS, et al. YC-1: a potential anticancer drug targeting hypoxia-inducible factor 1. J Natl Cancer Inst. 2003; 95:516–525.
32. Ahrens TD, Timme S, Hoeppner J, et al. Selective inhibition of esophageal cancer cells by combination of HDAC inhibitors and Azacytidine. Epigenetics. 2015; 10:431–445.
33. Cox TR, Rumney RM, Schoof EM, et al. The hypoxic cancer secretome induces pre-metastatic bone lesions through lysyl oxidase. Nature. 2015; 522:106–110.
34. Wells A, Grahovac J, Wheeler S, Ma B, Lauffenburger D. Targeting tumor cell motility as a strategy against invasion and metastasis. Trends Pharmacol Sci. 2013; 34:283–289.
35. Narumiya S, Tanji M, Ishizaki T. Rho signaling, ROCK and mDia1, in transformation, metastasis and invasion. Cancer Metastasis Rev. 2009; 28:65–76.
36. Gilkes DM, Xiang L, Lee SJ, et al. Hypoxia-inducible factors mediate coordinated RhoA-ROCK1 expression and signaling in breast cancer cells. Proc Natl Acad Sci USA. 2014; 111:E384–E393.
37. Semenza GL. Molecular mechanisms mediating metastasis of hypoxic breast cancer cells. Trends Mol Med. 2012; 18:534–543.
38. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011; 144:646–674.
39. Dewhirst MW, Cao Y, Moeller B. Cycling hypoxia and free radicals regulate angiogenesis and radiotherapy response. Nat Rev Cancer. 2008; 8:425–437.
40. Quail DF, Walsh LA, Zhang G, et al. Embryonic protein nodal promotes breast cancer vascularization. Cancer Res. 2012; 72:3851–3863.
41. Wang F, Lin F, Zhang P, et al. Thioredoxin-1 inhibitor, 1-methylpropyl 2-imidazolyl disulfide, inhibits the growth, migration and invasion of colorectal cancer cell lines. Oncol Rep. 2015; 33:967–973.
42. Welsh SJ, Williams RR, Birmingham A, Newman DJ, Kirkpatrick DL, Powis G. The thioredoxin redox inhibitors 1-methylpropyl 2-imidazolyl disulfide and pleurotin inhibit hypoxia-induced factor 1alpha and vascular endothelial growth factor formation. Mol Cancer Ther. 2003; 2:235–243.
43. Zhou J, Eleni C, Spyrou G, Brüne B. The mitochondrial thioredoxin system regulates nitric oxide-induced HIF-1alpha protein. Free Radic Biol Med. 2008; 44:91–98.
44. Welsh SJ, Bellamy WT, Briehl MM, Powis G. The redox protein thioredoxin-1 (Trx-1) increases hypoxia-inducible factor 1alpha protein expression: trx-1 overexpression results in increased vascular endothelial growth factor production and enhanced tumor angiogenesis. Cancer Res. 2002; 62:5089–5095.
45. Semenza GL. The hypoxic tumor microenvironment: a driving force for breast cancer progression. Biochim Biophys Acta. 2016; 1863:382–391.
46. Semenza GL. Novel strategies for cancer therapy. J Mol Med (Berl). 2016; 94:119–120.
47. Montagner M, Enzo E, Forcato M, et al. SHARP1 suppresses breast cancer metastasis by promoting degradation of hypoxia-inducible factors. Nature. 2012; 487:380–384.
48. Thienpont B, Steinbacher J, Zhao H, et al. Tumour hypoxia causes DNA hypermethylation by reducing TET activity. Nature. 2016; 537:63–68.